The Asia-Pacific diabetic assays market was valued at USD 0.62 billion in 2022 and is projected to reach USD 1.00 billion by 2030, exhibiting a compound annual growth rate (CAGR) of approximately 6% during the forecast period from 2023 to 2030. This growth is driven by the increasing prevalence of diabetes in the region, with China leading due to its high diabetes burden and rising investments...